跳至主要内容
临床试验/CTRI/2017/09/009938
CTRI/2017/09/009938进行中(未招募)4 期

Management using the Latest Technologies in Resource-Limited Settings to Optimize Combination Therapy after Viral Failure (Multi-OCTAVE) - MULTIOCTAVE

ational Institute Of Allergy and Infectious DiseasesNIAIDNIH0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
进行中(未招募)
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • NOTE: All potential participants with prior RAL exposure will be assigned to Cohort D.
  • 3.Current receipt of a PI-based regimen with no regimen change for a minimum of 24 weeks prior to screening.
  • NOTE A: Within the 30 days prior to collection of the confirmatory VF sample (see 4.1.4), alteration in dose, dose frequency, or any within-class substitution(s) for intolerance is permitted, as are drug interruptions for fewer than 7 cumulative days.
  • NOTE B: There can be no changes and no drug interruptions within the 3 days immediately prior to the collection of the confirmatory VF sample

排除标准

  • Contraindication to the proposed Step 2 ARV regimen as determined by the site investigator.
  • Indication for discontinuation of RAL, ETR, or DRV.

研究者

发起方
ational Institute Of Allergy and Infectious DiseasesNIAIDNIH

相似试验